➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Johnson and Johnson
Express Scripts
Medtronic
Colorcon

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,439,921

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,439,921 protect, and when does it expire?

Patent 9,439,921 protects KENGREAL and is included in one NDA.

This patent has ten patent family members in ten countries.

Summary for Patent: 9,439,921
Title:Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Inventor(s): Dutta; Panna (Flemington, NJ), Rafai Far; Adel (Mount-Royal, CA), Ding; Min (Irvington, NY), Motheram; Rajeshwar (Dayton, NJ)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ)
Application Number:15/049,727
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,439,921
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 9,439,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,439,921

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112017014996   Start Trial
Canada 2971868   Start Trial
Chile 2017001840   Start Trial
China 107206014   Start Trial
European Patent Office 3244900   Start Trial
South Korea 20170103848   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Baxter
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.